# APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors

Source: https://onco.cc/trials/nct04785196/  
OnCo record `nct04785196` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Toripalimab in sarcomas, run by Ascentage Pharma Group Inc., now recruiting.

## Summary

APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT04785196 by Ascentage Pharma Group Inc., with 95 participants planned, started 2021-05-26 and due to reach its primary completion in 2026-04. Interventions recorded: APG-115 and Toripalimab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04785196
- Phase: 1/2
- Setting: A Phase Ib/II Study of APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Other Advanced Solid Tumors
- Sponsor: Ascentage Pharma Group Inc.
- Enrolled: 95

## Sources

- ClinicalTrials.gov NCT04785196: https://clinicaltrials.gov/study/NCT04785196

## Connected records

- cancers: [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- drugs: [Toripalimab](https://onco.cc/drugs/toripalimab/)
- companies: [Ascentage Pharma](https://onco.cc/companies/ascentage-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct04785196.json